Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

1998-06

AUTHORS

Peter D. Kwong, Richard Wyatt, James Robinson, Raymond W. Sweet, Joseph Sodroski, Wayne A. Hendrickson

ABSTRACT

The entry of human immunodeficiency virus (HIV) into cells requires the sequential interaction of the viral exterior envelope glycoprotein, gp120, with the CD4 glycoprotein and a chemokine receptor on the cell surface. These interactions initiate a fusion of the viral and cellular membranes. Although gpl20 can elicit virus-neutralizing antibodies, HIV eludes the immune system. We have solved the X-ray crystal structure at 2.5 Å resolution of an HIV-1 gp120 core complexed with a two-domain fragment of human CD4 and an antigen-binding fragment of a neutralizing antibody that blocks chemokine-receptor binding. The structure reveals a cavity-laden CD4–gp120 interface, a conserved binding site for the chemokine receptor, evidence for a conformational change upon CD4 binding, the nature of a CD4-induced antibody epitope, and specific mechanisms for immune evasion. Our results provide a framework for understanding the complex biology of HIV entry into cells and should guide efforts to intervene. More... »

PAGES

648-659

Journal

TITLE

Nature

ISSUE

6686

VOLUME

393

Related Patents

  • Compositions And Methods For Inducing Protective Immunity Against Human Immunodeficiency Virus Infection
  • Carbohydrate-Based Synthetic Vaccines For Hiv
  • Contacting With Monoclonal Antibody Which Binds To Chemokine Receptor; Blocks Fusion And Inhibits Activation Of Inflammatory Response; Inhibiting Fusion Of Hiv-1 To Cd4+ Cells
  • Live Cell Biosensors
  • Method For Treating Psoriasis
  • Image Processing Method And System For Microfluidic Devices
  • Preventing The Viral Entry Process Into Target Cells, By Inhibiting The Binding Of Viral Surface Glycoprotein To Cell Surface Cd4, To Fusion Coreceptors Ccr5 Chemokine Receptors And The Transient Conformation Fusion Intermediate That Ultimately Folds Into A Conformation Capable Of Mediating Fusion
  • Polynucleotides Encoding Antigenic Hiv Type C Polypeptides, Polypeptides And Uses Thereof
  • Recombinant Hiv-1 Envelope Proteins And Their Use
  • Engineered Lectin Oligomers With Antiviral Activity
  • Fusion Proteins Comprising Cd4 Minimal Modules And Invasin Polypeptides That Are Capable Of Binding To The Hiv Envelope And Exposing Cryptic Neutraliziation Epitopes
  • Trimer Stabilizing Hiv Envelope Protein Mutations
  • Method Of Inducing An Antiviral Immune Response Against Hiv-1 Utilizing Chimeric Hiv Env Proteins Comprising Cd4 Mini-Proteins Or Cd4 Mimetics
  • Hcv-Derived Polypeptides And Uses Thereof
  • Method For The Production Of Antibodies That Bind To Multiple Membrane Spanning Proteins
  • Highly Active Agonistic Cd4 Binding Site Anti-Hiv Antibodies (Haads) Comprising Modified Cdrh2 Regions That Improve Contact With Gp120
  • Highly Active Agonistic Cd4 Binding Site Anti-Hiv Antibodies (Haads) Comprising Modified Cdrh2 Regions That Improve Contact With Gp120
  • Integrated Chip Carriers With Thermocycler Interfaces And Methods Of Using The Same
  • Chimeric Hiv Env Proteins Comprising Cd4 Mini-Proteins Or Cd4 Mimetics That Are Capable Of Inducing Neutralizing Antibody Responses Against Cryptic Env Epitopes
  • Signature-Based Human Immunodeficiency Virus (Hiv) Envelope (Env) Trimer Vaccines And Methods Of Using The Same
  • Methods For Inducing An Immune Response Against Human Immunodeficiency Virus Infection In Subjects Undergoing Antiretroviral Treatment
  • Anti-Ccr5 Antibody
  • Identification Of Novel Broadly Cross-Reactive Hiv-1 Neutralizing Human Monoclonal Antibodies
  • Humanized Anti-Cd4 Antibody With Immunosuppressive Properties
  • Viral Plasmid For Use In Treatment And Prevention Of Viral Diseases; Gene Therapy; Gene Expression Inhibition; Antisense Therapy
  • Phenylboronic Acid Compounds As Antiviral Agents
  • Identifying Preferential Immunoglobulins For Use In Treatment And Prevention Of Infections And Cell Proliferative Disorders Via Repeated Screening Of Phage Library
  • Biochemically Stabilized Hiv-1 Env Trimer Vaccine
  • Methods For Inducing Protective Immunity Against Human Immunodeficiency Virus Infection
  • Microfluidic Devices For Performing High Throughput Screening Or Crystallization Of Target Materials; Increased Throughput And Reduction Of Reaction Volumes
  • Human Immunodeficiency Virus Type 1 (Hiv-1)-Neutralizing Human Single-Chain Antibodies With Improved Breadth And Potency
  • Modified Phage For Displaying Post-Translationally Modified Proteins And Uses Thereof
  • Conformationally Stabilized Hiv Envelope Immunogens And Triggering Hiv-I Envelope To Reveal Cryptic V3-Loop Epitopes
  • Hiv Vaccine Formulation
  • Chimeric Human Immunodeficiency Virus (Hiv) Immunogens Comprising Gag P24-P17 Fused To Multiple Cytotoxic T Lymphocyte (Ctl) Epitopes
  • Stabilized Human Immunodeficiency Virus (Hiv) Envelope (Env) Trimer Vaccines And Methods Of Using Same
  • Methods And Compositions For Inducing Protective Immunity Against Human Immunodeficiency Virus Infection
  • Stabilized Mosaic Human Immunodeficiency Virus Type 1 (Hiv-1) Gp140 Envelope (Env) Trimers
  • Microfluidic Devices For Performing High Throughput Screening Or Crystallization Of Target Materials; Increased Throughput And Reduction Of Reaction Volumes
  • Relates To Immunogen For Inducing Antibodies That Neutralize A Wide Spectrum Of Hiv Primary Isolates And Method Of Inducing Anti-Hiv Antibodies Using Such Immunogen
  • Rapid Selection Method For Hiv Gp-120 Variants
  • Recombinant Adenoviruses Encoding Mosaic Human Immunodeficiency Virus (Hiv) Env, Gag, And Pol Antigens
  • Microfluidic Reaction Apparatus For High Throughput Screening
  • Conformationally Stabilized Hiv Envelope Immunogens
  • Multilayered Microfluidic Apparatus For Positioning Protein Crystal Within An Energy Beam; High Throughput Assay; Protein Structure Analysis
  • Consensus/Ancestral Immunogens
  • Mannose Immunogens For Hiv-1
  • Antibodies Directed Toward The Hiv-1 Gp120 Cd4 Binding Site With Increased Potency And Breadth
  • Methods For Identifying Aptamer Regulators
  • Stabilized Human Immunodeficiency Virus (Hiv) Clade C Envelope (Env) Trimer Vaccines And Methods Of Using Same
  • Poxvirus Vectors Encoding Hiv Antigens, And Methods Of Use Thereof
  • Microfluidic Free Interface Diffusion Techniques
  • Methods For Assaying Inhibition Of Hiv-1 Envelope Glycoprotein-Mediated Membrane Fusion
  • Integrated Chip Carriers With Thermocycler Interfaces And Methods Of Using The Same
  • Recombinant Measles Viruses Expressing Epitopes Of Antigens Of Rna Viruses And Use Of The Recombinant Viruses For The Preparation Of Vaccine Compositions
  • Compositions And Methods For Inducing Hiv-1 Antibodies
  • Neutralizing Bispecific Fusion Protein That Binds To Two Sites On A Single Gp120 Molecule, Comprising A First Scd4 Binding Domain Which Binds To An Inducing Site On The Gp120 And A Second Binding Domain That Binds To And Forms A Neutralizing Complex With The Induced Epitope Of The Same Gp120;
  • Anti-Ccr5 Antibody
  • Contacting Each Of A Plurality Of Reagents In Separate Compartments With Compound, Wherein Each Reagent Has A Predetermined Concentration Of Two Types Of Precipitating Agents Comprising Salt And Polyoxyethylene Glycol; Human Immunodeficiency Polypeptide Viral Polypeptides;
  • Chimeric Protein For Prevention And Treatment Of Hiv Infection
  • Microfluidic Free Interface Diffusion Techniques
  • Agent For Treating Disease
  • Biochemically Stabilized Hiv-1 Env Trimer Vaccine
  • Preventing Fusion Of Virus And Preferential Cells; Incubate Cells With Genetically Engineered Viral Particles And Viricide, Detect Reduction In Emission Energy, Reduction In Emission Indicates Prevention Of Viral Fusion And Infection
  • Microfluidic Free Interface Diffusion Techniques
  • Microfluidic Free Interface Diffusion Techniques
  • Peptidic Antigen That Induces Antibody Recognizing Three-Dimensional Structure Of Hiv And Method For Synthesizing Same
  • Microfluidic Protein Crystallography Techniques
  • Biochemically Stabilized Hiv-1 Env Trimer Vaccine
  • Compositions And Methods For Inhibition Of Hiv-1 Infection
  • Polynucleotides Encoding Antigenic Hiv Type C Polypeptides, Polypeptides And Uses Thereof
  • Methods To Identify Immunogens By Targeting Improbable Mutations
  • Isolation, Purification Human Immunodeficiency Virus Mutant; Glycoprotein
  • Treating A Subject Afflicted With Hiv-1 By Administering Anti-Viral Agent Selected From A Nonnucleoside Reverse Transcriptase Inhibitor, A Nucleoside Reverse Transcriptase Inhibitor, A Hiv-1 Protease Inhibitor, And A Hiv-1 Fusion Or Viral Entry Inhibitor
  • Highly Active Agonistic Cd4 Binding Site Anti-Hiv Antibodies (Haads) Comprising Modified Cdrh2 Regions That Improve Contact With Gp120
  • Chimeric Antigen Receptors To Control Hiv Infection
  • Biochemically Stabilized Hiv-1 Env Trimer Vaccine
  • High Throughput Screening Of Crystallization Of Materials
  • Contacting With Monoclonal Antibody Which Binds To Chemokine Receptor; Blocks Fusion And Inhibits Activation Of Inflammatory Response
  • Systems And Methods For Mixing Reactants
  • Peptidic Antigen That Induces Antibody Recognizing Three-Dimensional Structure Of Hiv And Method For Synthesizing Same
  • Cell Free Methods For Detecting Protein-Ligand Binding
  • Broadly Cross-Reactive Neutralizing Antibodies Against Human Immunodeficiency Virus Selected By Env-Cd4-Co-Receptor Complexes
  • Neutralizing Antibodies To Hiv-1 And Their Use
  • Human Immunodeficiency Virus-Neutralizing Human Antibodies With Improved Breadth And Potency
  • Method For Generating Immune Responses Utilizing Nucleic Acids Encoding Fusion Proteins Comprising Cd4 Minimal Modules And Invasin Polypeptides That Are Capable Of Binding To The Hiv Envelope And Exposing Cryptic Neutralization Epitopes
  • Synthetic Peptides And Uses Therefore
  • Monoclonal Antibody Against The Ccr5 Chemokine Receptor
  • Compositions, Method And Kits Relating To Deletion Mutations Of Immunodeficiency Virus Gp120 Hypervariable Regions
  • Chemokine Coreceptor Fusion For Use Prevention And Treatment Of Viral Infection; Immunotherapy
  • Synthesizing Vaccines, Immunogens, And Antibodies
  • Biochemically Stabilized Hiv-1 Env Trimer Vaccine
  • Method For Producing A Nucleotide Sequence Construct With Optimized Codons For An Hiv Genetic Vaccine Based On A Primary, Early Hiv Isolate And Synthetic Envelope Bx08 Constructs
  • Microfluidic Reaction Apparatus For High Throughput Screening
  • Hiv Gp120 Crystal Structure And Its Use To Identify Immunogens
  • Labeled Peptides, Proteins And Antibodies And Processes And Intermediates Useful For Their Preparation
  • Method For Treating Psoriasis
  • Conformationally Stabilized Hiv Envelope Immunogens And Triggering Hiv-1 Envelope To Reveal Cryptic V3-Loop Epitopes
  • High Throughput Screening Of Crystallization Of Materials
  • Envelope Proteins (Env) Comprising Cd4 (And Mimetics) Binding Site And Deletion Region; Maintains Structural Conformation Of Complementary Determining Region 2-Like Loop; Insertion Near Chemokine Receptor Binding Site; Vectors, Cells; Liposomes
  • Small Molecule Cd4 Mimetics And Uses Thereof
  • Envelope Proteins (Env) Comprising Cd4 (And Mimetics) Binding Site And Deletion Region; Maintains Structural Conformation Of Complementary Determining Region 2-Like Loop; Insertion Near Chemokine Receptor Binding Site; Vectors, Cells; Liposomes
  • Hiv Gp120 Crystal Structure And Its Use To Identify Immunogens
  • Conformationally Stabilized Hiv Envelope Immunogens And Triggering Hiv-1 Envelope To Reveal Cryptic V3-Loop Epitopes
  • Labeled Peptides, Proteins And Antibodies And Processes And Intermediates Useful For Their Preparation
  • Hiv Gp120 Crystal Structure And Its Use To Identify Immunogens
  • Method For Treating Psoriasis
  • Biochemically Stabilized Hiv-1 Env Trimer Vaccine
  • Molecular Clones With Mutated Hiv Gag/Pol, Siv Gag And Siv Env Genes
  • Method For Producing A Nucleotide Sequence Construct With Optimized Codons For An Hiv Genetic Vaccine Based On A Primary, Early Hiv Isolate And Synthetic Envelope Bx08 Constructs
  • High Throughput Screening Of Crystallization Of Materials
  • Neutralizing Antibodies To Hiv-1 And Their Use
  • Rapid Expression Cloning Of Human Monoclonal Antibodies From Memory B Cells
  • Use Of A Native Epitope For Selecting Evolved Binding Members From A Library Of Mutants Of A Protein Capable Of Binding To Said Epitope
  • Broadly Neutralizing Hiv-1 Vrc07 Antibodies That Bind To The Cd4-Binding Site Of The Envelope Protein
  • Method Of Generating An Immune Response In A Subject Using Fusion Proteins Comprising Cd4 Minimal Modules And Hiv Tat Scaffold Polypeptides That Are Capable Of Binding To The Hiv Envelope And Exposing Cryptic Neutralization Epitopes
  • Synthetic Human Immunodeficiency Virus (Hiv) Envelope Antigen, Vectors, And Compositions Thereof
  • Microfluidic Reaction Apparatus For High Throughput Screening
  • Compositions And Methods For Inducing Hiv-1 Antibodies
  • Immunogenic Compositions Derived From Structural Alteration Of Hiv Envelope Proteins
  • Conformationally Stabilized Hiv Envelope Immunogens And Triggering Hiv-1 Envelope To Reveal Cryptic V3-Loop Epitopes
  • Neutralizing Antibodies To Hiv-1 And Their Use
  • High Throughput Screening Of Crystallization Of Materials
  • Microfludic Protein Crystallography Techniques
  • Fusion Protein For Hiv-1 Gp120 Antigen Detection
  • Recombinant Hiv-1 Envelope Proteins And Their Use
  • Immunogen Comprising An Hiv Envelope Protein, A Ligand And H2 Peptide
  • Humanized Anti-Cd4 Antibody With Immunosuppressive Properties
  • Two Gp120 Binding Molecules That Target The Cd4 Binding Pocket On A Trimeric Hiv Gp120 Complex And Gp120 Binding Molecules Are Separated By A Spacer/Linker Of Sufficient Length To Provide For Binding Of The Gp120 Binding Molecules To The Cd-4 Binding Sites On Trimeric Gp120 Sites On Virion Surface
  • Immunogen Comprising Ligand Bound Hiv Envelope Protein
  • Hiv Vaccine Formulation
  • Forming Antibodies
  • Labeled Peptides, Proteins And Antibodies And Processes And Intermediates Useful For Their Preparation
  • Peptide Which Can Induce Antibody Capable Of Recognizing Stereostructure Of Hiv
  • Broadly Neutralizing Hiv-1 Vrc07 Antibodies That Bind To The Cd4-Binding Site Of The Envelope Protein
  • Humanized Anti-Cd4 Antibody With Immunosuppressive Properties
  • Stabilized Single Human Cd4 Domains And Fusion Proteins
  • Novel Drug Target Site Within Gp120 Of Hiv
  • Identification Of Novel Broadly Cross-Reactive Hiv-1 Neutralizing Human Monoclonal Antibodies
  • An Hiv-1 Gp120 Mini V3 Loop And Uses Thereof
  • High Throughput Screening Of Crystallization Materials
  • Trimer Stabilizing Hiv Envelope Protein Mutations
  • Fret-Based Reagents And Methods For Identifying Anti-Hiv Compounds
  • Broadly Neutralizing Hiv-1 Antibodies That Bind To The Cd4-Binding Site Of The Envelope Protein
  • Method For Screening For An Anti-Cd4 Antibody Suitable For Use In Immunotherapy
  • Microfluidic Protein Crystallography
  • Stabilized Human Immunodeficiency Virus (Hiv) Envelope (Env) Trimer Vaccines And Methods Of Using Same
  • Anti-Ccr5 Antibody
  • Crystal Forming Devices And Systems And Methods For Using The Same
  • Modified Human Immunodeficiency Virus Type 1 (Hiv-1) Group M Consensus Envelope Glycoproteins Capable Of Inducing Broadly Reactive T- And B-Cell Responses
  • Immunogen Comprising An Hiv Envelope Protein, A Ligand And H2 Peptide
  • Neutralizing Antibodies To Hiv-1 And Their Use
  • Microfluidic Free Interface Diffusion Techniques
  • Methods For Inhibiting Hiv-1 Replication Involving The Administration Of An Anti-Ccr5 Receptor Monoclonal Antibody And Small Molecule Ccr5 Receptor Antagonist
  • Inhibitors Of Hiv-1 Entry And Methods Of Use Thereof
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/31405

    DOI

    http://dx.doi.org/10.1038/31405

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1038246480

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/9641677


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Biological Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0601", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Biochemistry and Cell Biology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Immunology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1108", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical Microbiology", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Amino Acid Sequence", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Animals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "CD4 Antigens", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "CHO Cells", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cricetinae", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cricetulus", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Crystallography, X-Ray", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Glycosylation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "HIV Antibodies", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "HIV Envelope Protein gp120", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "HIV Envelope Protein gp41", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunoglobulin Fragments", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Membrane Fusion", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Models, Molecular", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Molecular Sequence Data", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neutralization Tests", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Protein Conformation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Receptors, CCR5", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Department of Biochemistry and Molecular Biophysics, Columbia University, 10032, New York, New York, USA", 
              "id": "http://www.grid.ac/institutes/grid.21729.3f", 
              "name": [
                "Department of Biochemistry and Molecular Biophysics, Columbia University, 10032, New York, New York, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Kwong", 
            "givenName": "Peter D.", 
            "id": "sg:person.0612551152.66", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0612551152.66"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Cancer Immunology and AIDS, Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard School of Public Health, 02115, Boston, Massachusetts, USA", 
              "id": "http://www.grid.ac/institutes/grid.65499.37", 
              "name": [
                "Department of Cancer Immunology and AIDS, Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard School of Public Health, 02115, Boston, Massachusetts, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Wyatt", 
            "givenName": "Richard", 
            "id": "sg:person.0756353131.25", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0756353131.25"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Pediatrics, Tulane University Medical Center, 1430 Tulane Avenue, 70112, New Orleans, Louisiana, USA", 
              "id": "http://www.grid.ac/institutes/grid.412823.e", 
              "name": [
                "Department of Pediatrics, Tulane University Medical Center, 1430 Tulane Avenue, 70112, New Orleans, Louisiana, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Robinson", 
            "givenName": "James", 
            "id": "sg:person.01107475021.14", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01107475021.14"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Immunology, SmithKline Beecham Pharmaceuticals, 709 Swedeland Road, 19406, King of Prussia, Pennsylvania, USA", 
              "id": "http://www.grid.ac/institutes/grid.418019.5", 
              "name": [
                "Department of Immunology, SmithKline Beecham Pharmaceuticals, 709 Swedeland Road, 19406, King of Prussia, Pennsylvania, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Sweet", 
            "givenName": "Raymond W.", 
            "id": "sg:person.013242604132.30", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013242604132.30"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Immunology and Infectious Diseases, Harvard School of Public Health, 02115, Boston, Massachusetts, USA", 
              "id": "http://www.grid.ac/institutes/grid.38142.3c", 
              "name": [
                "Department of Cancer Immunology and AIDS, Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard School of Public Health, 02115, Boston, Massachusetts, USA", 
                "Department of Immunology and Infectious Diseases, Harvard School of Public Health, 02115, Boston, Massachusetts, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Sodroski", 
            "givenName": "Joseph", 
            "id": "sg:person.01365275476.29", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01365275476.29"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Howard Hughes Medical Institute, Columbia University, 10032, New York, New York, USA", 
              "id": "http://www.grid.ac/institutes/grid.21729.3f", 
              "name": [
                "Department of Biochemistry and Molecular Biophysics, Columbia University, 10032, New York, New York, USA", 
                "Howard Hughes Medical Institute, Columbia University, 10032, New York, New York, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hendrickson", 
            "givenName": "Wayne A.", 
            "id": "sg:person.01240471215.59", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240471215.59"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/31514", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007469332", 
              "https://doi.org/10.1038/31514"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/355740a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008705802", 
              "https://doi.org/10.1038/355740a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/371037a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1046282624", 
              "https://doi.org/10.1038/371037a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/348419a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1025743531", 
              "https://doi.org/10.1038/348419a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/387426a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010263645", 
              "https://doi.org/10.1038/387426a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/384179a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017723508", 
              "https://doi.org/10.1038/384179a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/289366a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1016242659", 
              "https://doi.org/10.1038/289366a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/387527a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1018440913", 
              "https://doi.org/10.1038/387527a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/348411a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023911798", 
              "https://doi.org/10.1038/348411a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nsb1295-1075", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1049045339", 
              "https://doi.org/10.1038/nsb1295-1075"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/340571a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1049274163", 
              "https://doi.org/10.1038/340571a0"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "1998-06", 
        "datePublishedReg": "1998-06-01", 
        "description": "The entry of human immunodeficiency virus (HIV) into cells requires the sequential interaction of the viral exterior envelope glycoprotein, gp120, with the CD4 glycoprotein and a chemokine receptor on the cell surface. These interactions initiate a fusion of the viral and cellular membranes. Although gpl20 can elicit virus-neutralizing antibodies, HIV eludes the immune system. We have solved the X-ray crystal structure at 2.5\u2009\u00c5 resolution of an HIV-1 gp120 core complexed with a two-domain fragment of human CD4 and an antigen-binding fragment of a neutralizing antibody that blocks chemokine-receptor binding. The structure reveals a cavity-laden CD4\u2013gp120 interface, a conserved binding site for the chemokine receptor, evidence for a conformational change upon CD4 binding, the nature of a CD4-induced antibody epitope, and specific mechanisms for immune evasion. Our results provide a framework for understanding the complex biology of HIV entry into cells and should guide efforts to intervene.", 
        "genre": "article", 
        "id": "sg:pub.10.1038/31405", 
        "isAccessibleForFree": true, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.2510953", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1018957", 
            "issn": [
              "0028-0836", 
              "1476-4687"
            ], 
            "name": "Nature", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "6686", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "393"
          }
        ], 
        "keywords": [
          "human immunodeficiency virus", 
          "chemokine receptors", 
          "envelope glycoprotein", 
          "HIV gp120 envelope glycoprotein", 
          "virus-neutralizing antibodies", 
          "exterior envelope glycoprotein", 
          "elicit virus-neutralizing antibodies", 
          "chemokine receptor binding", 
          "gp120 envelope glycoprotein", 
          "immunodeficiency virus", 
          "HIV-1 gp120 core", 
          "HIV entry", 
          "human CD4", 
          "immune evasion", 
          "CD4 receptor", 
          "immune system", 
          "CD4 binding", 
          "CD4 glycoprotein", 
          "human antibodies", 
          "antigen-binding fragments", 
          "antibodies", 
          "receptors", 
          "antibody epitopes", 
          "gp120 core", 
          "complex biology", 
          "specific mechanisms", 
          "glycoprotein", 
          "cell surface", 
          "cells", 
          "CD4", 
          "gpl20", 
          "gp120", 
          "epitopes", 
          "virus", 
          "binding", 
          "entry", 
          "cellular membranes", 
          "sequential interactions", 
          "evasion", 
          "evidence", 
          "fragments", 
          "changes", 
          "mechanism", 
          "membrane", 
          "fusion", 
          "biology", 
          "sites", 
          "two-domain fragment", 
          "interaction", 
          "results", 
          "efforts", 
          "complexes", 
          "system", 
          "resolution", 
          "conformational changes", 
          "nature", 
          "structure", 
          "surface", 
          "core", 
          "framework", 
          "X-ray crystal structure", 
          "interface", 
          "crystal structure"
        ], 
        "name": "Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody", 
        "pagination": "648-659", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1038246480"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/31405"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "9641677"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/31405", 
          "https://app.dimensions.ai/details/publication/pub.1038246480"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-11-24T20:48", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_286.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1038/31405"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/31405'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/31405'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/31405'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/31405'


     

    This table displays all metadata directly associated to this object as RDF triples.

    308 TRIPLES      21 PREDICATES      122 URIs      100 LITERALS      26 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/31405 schema:about N13f2397579d84475b71ad3134b01aacb
    2 N17c1add79a5f4da4bddcd1d1e449409e
    3 N1b449c81977d45f086465ca6cfa5782d
    4 N38463ec716b04806b41810e48ebdd200
    5 N57ab92e8098947e7a556d08f92044bd5
    6 N80f43ca9fe204aa3b47e7e72519f24a1
    7 N8eb7b9a1a9a24ce3868c03e70fdedaaf
    8 N9b4c7172d7194409b4a5eaf06c6a4130
    9 N9ed086dd4efc4dc5b1e1f84926817415
    10 Na5c7225198514573b1eaad389589b3ef
    11 Nb1eea459faa646dda78031543e4368e7
    12 Nb77f453160164a82be1fc6a96542c9d6
    13 Nbdc6dad60fc9401a80b663a4b52b8b97
    14 Nc1b188833e46433d8d4aead757cba6ca
    15 Nc84189d082fa4984b3d6b40d468898b3
    16 Nd38533920b704fbfa34b79cddcefda56
    17 Nd4fdec1a33f04682a2997ce622a3b730
    18 Ndf801ec6967c491181d3b142292d3702
    19 Ne688bf16927548d5b479c8c060bf70a9
    20 anzsrc-for:06
    21 anzsrc-for:0601
    22 anzsrc-for:11
    23 anzsrc-for:1107
    24 anzsrc-for:1108
    25 schema:author N4292b287e44e4949847c4f67a3ce96e5
    26 schema:citation sg:pub.10.1038/289366a0
    27 sg:pub.10.1038/31514
    28 sg:pub.10.1038/340571a0
    29 sg:pub.10.1038/348411a0
    30 sg:pub.10.1038/348419a0
    31 sg:pub.10.1038/355740a0
    32 sg:pub.10.1038/371037a0
    33 sg:pub.10.1038/384179a0
    34 sg:pub.10.1038/387426a0
    35 sg:pub.10.1038/387527a0
    36 sg:pub.10.1038/nsb1295-1075
    37 schema:datePublished 1998-06
    38 schema:datePublishedReg 1998-06-01
    39 schema:description The entry of human immunodeficiency virus (HIV) into cells requires the sequential interaction of the viral exterior envelope glycoprotein, gp120, with the CD4 glycoprotein and a chemokine receptor on the cell surface. These interactions initiate a fusion of the viral and cellular membranes. Although gpl20 can elicit virus-neutralizing antibodies, HIV eludes the immune system. We have solved the X-ray crystal structure at 2.5 Å resolution of an HIV-1 gp120 core complexed with a two-domain fragment of human CD4 and an antigen-binding fragment of a neutralizing antibody that blocks chemokine-receptor binding. The structure reveals a cavity-laden CD4–gp120 interface, a conserved binding site for the chemokine receptor, evidence for a conformational change upon CD4 binding, the nature of a CD4-induced antibody epitope, and specific mechanisms for immune evasion. Our results provide a framework for understanding the complex biology of HIV entry into cells and should guide efforts to intervene.
    40 schema:genre article
    41 schema:isAccessibleForFree true
    42 schema:isPartOf N2a6d6132b6f74a06a47202c8eaaa222a
    43 Ncfbfb0e6c4d643149bbf06e7e8a659c3
    44 sg:journal.1018957
    45 schema:keywords CD4
    46 CD4 binding
    47 CD4 glycoprotein
    48 CD4 receptor
    49 HIV entry
    50 HIV gp120 envelope glycoprotein
    51 HIV-1 gp120 core
    52 X-ray crystal structure
    53 antibodies
    54 antibody epitopes
    55 antigen-binding fragments
    56 binding
    57 biology
    58 cell surface
    59 cells
    60 cellular membranes
    61 changes
    62 chemokine receptor binding
    63 chemokine receptors
    64 complex biology
    65 complexes
    66 conformational changes
    67 core
    68 crystal structure
    69 efforts
    70 elicit virus-neutralizing antibodies
    71 entry
    72 envelope glycoprotein
    73 epitopes
    74 evasion
    75 evidence
    76 exterior envelope glycoprotein
    77 fragments
    78 framework
    79 fusion
    80 glycoprotein
    81 gp120
    82 gp120 core
    83 gp120 envelope glycoprotein
    84 gpl20
    85 human CD4
    86 human antibodies
    87 human immunodeficiency virus
    88 immune evasion
    89 immune system
    90 immunodeficiency virus
    91 interaction
    92 interface
    93 mechanism
    94 membrane
    95 nature
    96 receptors
    97 resolution
    98 results
    99 sequential interactions
    100 sites
    101 specific mechanisms
    102 structure
    103 surface
    104 system
    105 two-domain fragment
    106 virus
    107 virus-neutralizing antibodies
    108 schema:name Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
    109 schema:pagination 648-659
    110 schema:productId N1ea9f9d38da94f7a986cc21f1d697608
    111 N5edf4fa5afe046c5b784b6d1d58e8e34
    112 Ned230765af7c442cad8fd58dcbf59870
    113 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038246480
    114 https://doi.org/10.1038/31405
    115 schema:sdDatePublished 2022-11-24T20:48
    116 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    117 schema:sdPublisher Ne4976dbc76cc429388069c6ea917b718
    118 schema:url https://doi.org/10.1038/31405
    119 sgo:license sg:explorer/license/
    120 sgo:sdDataset articles
    121 rdf:type schema:ScholarlyArticle
    122 N13f2397579d84475b71ad3134b01aacb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    123 schema:name CHO Cells
    124 rdf:type schema:DefinedTerm
    125 N17c1add79a5f4da4bddcd1d1e449409e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    126 schema:name HIV Envelope Protein gp41
    127 rdf:type schema:DefinedTerm
    128 N1b449c81977d45f086465ca6cfa5782d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    129 schema:name Crystallography, X-Ray
    130 rdf:type schema:DefinedTerm
    131 N1ea9f9d38da94f7a986cc21f1d697608 schema:name dimensions_id
    132 schema:value pub.1038246480
    133 rdf:type schema:PropertyValue
    134 N2a6d6132b6f74a06a47202c8eaaa222a schema:issueNumber 6686
    135 rdf:type schema:PublicationIssue
    136 N38463ec716b04806b41810e48ebdd200 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    137 schema:name Protein Conformation
    138 rdf:type schema:DefinedTerm
    139 N4292b287e44e4949847c4f67a3ce96e5 rdf:first sg:person.0612551152.66
    140 rdf:rest Nafd837bf67a04b4aa4002995ecd7fd2a
    141 N57ab92e8098947e7a556d08f92044bd5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    142 schema:name Models, Molecular
    143 rdf:type schema:DefinedTerm
    144 N5edf4fa5afe046c5b784b6d1d58e8e34 schema:name pubmed_id
    145 schema:value 9641677
    146 rdf:type schema:PropertyValue
    147 N5f9386807ced448a9a88cb99c5da098e rdf:first sg:person.01365275476.29
    148 rdf:rest Ne97a40c348184f979ceb1f518e0f9f57
    149 N77aae7adff8d4a339185b2720581da97 rdf:first sg:person.01107475021.14
    150 rdf:rest N9b97d5838e9c4d328ae53ed744a8a261
    151 N80f43ca9fe204aa3b47e7e72519f24a1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    152 schema:name HIV Antibodies
    153 rdf:type schema:DefinedTerm
    154 N8eb7b9a1a9a24ce3868c03e70fdedaaf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    155 schema:name Glycosylation
    156 rdf:type schema:DefinedTerm
    157 N9b4c7172d7194409b4a5eaf06c6a4130 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    158 schema:name Cricetulus
    159 rdf:type schema:DefinedTerm
    160 N9b97d5838e9c4d328ae53ed744a8a261 rdf:first sg:person.013242604132.30
    161 rdf:rest N5f9386807ced448a9a88cb99c5da098e
    162 N9ed086dd4efc4dc5b1e1f84926817415 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    163 schema:name Receptors, CCR5
    164 rdf:type schema:DefinedTerm
    165 Na5c7225198514573b1eaad389589b3ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    166 schema:name Neutralization Tests
    167 rdf:type schema:DefinedTerm
    168 Nafd837bf67a04b4aa4002995ecd7fd2a rdf:first sg:person.0756353131.25
    169 rdf:rest N77aae7adff8d4a339185b2720581da97
    170 Nb1eea459faa646dda78031543e4368e7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    171 schema:name Molecular Sequence Data
    172 rdf:type schema:DefinedTerm
    173 Nb77f453160164a82be1fc6a96542c9d6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    174 schema:name CD4 Antigens
    175 rdf:type schema:DefinedTerm
    176 Nbdc6dad60fc9401a80b663a4b52b8b97 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    177 schema:name Animals
    178 rdf:type schema:DefinedTerm
    179 Nc1b188833e46433d8d4aead757cba6ca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    180 schema:name Membrane Fusion
    181 rdf:type schema:DefinedTerm
    182 Nc84189d082fa4984b3d6b40d468898b3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    183 schema:name HIV Envelope Protein gp120
    184 rdf:type schema:DefinedTerm
    185 Ncfbfb0e6c4d643149bbf06e7e8a659c3 schema:volumeNumber 393
    186 rdf:type schema:PublicationVolume
    187 Nd38533920b704fbfa34b79cddcefda56 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    188 schema:name Immunoglobulin Fragments
    189 rdf:type schema:DefinedTerm
    190 Nd4fdec1a33f04682a2997ce622a3b730 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    191 schema:name Amino Acid Sequence
    192 rdf:type schema:DefinedTerm
    193 Ndf801ec6967c491181d3b142292d3702 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    194 schema:name Humans
    195 rdf:type schema:DefinedTerm
    196 Ne4976dbc76cc429388069c6ea917b718 schema:name Springer Nature - SN SciGraph project
    197 rdf:type schema:Organization
    198 Ne688bf16927548d5b479c8c060bf70a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    199 schema:name Cricetinae
    200 rdf:type schema:DefinedTerm
    201 Ne97a40c348184f979ceb1f518e0f9f57 rdf:first sg:person.01240471215.59
    202 rdf:rest rdf:nil
    203 Ned230765af7c442cad8fd58dcbf59870 schema:name doi
    204 schema:value 10.1038/31405
    205 rdf:type schema:PropertyValue
    206 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
    207 schema:name Biological Sciences
    208 rdf:type schema:DefinedTerm
    209 anzsrc-for:0601 schema:inDefinedTermSet anzsrc-for:
    210 schema:name Biochemistry and Cell Biology
    211 rdf:type schema:DefinedTerm
    212 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    213 schema:name Medical and Health Sciences
    214 rdf:type schema:DefinedTerm
    215 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
    216 schema:name Immunology
    217 rdf:type schema:DefinedTerm
    218 anzsrc-for:1108 schema:inDefinedTermSet anzsrc-for:
    219 schema:name Medical Microbiology
    220 rdf:type schema:DefinedTerm
    221 sg:grant.2510953 http://pending.schema.org/fundedItem sg:pub.10.1038/31405
    222 rdf:type schema:MonetaryGrant
    223 sg:journal.1018957 schema:issn 0028-0836
    224 1476-4687
    225 schema:name Nature
    226 schema:publisher Springer Nature
    227 rdf:type schema:Periodical
    228 sg:person.01107475021.14 schema:affiliation grid-institutes:grid.412823.e
    229 schema:familyName Robinson
    230 schema:givenName James
    231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01107475021.14
    232 rdf:type schema:Person
    233 sg:person.01240471215.59 schema:affiliation grid-institutes:grid.21729.3f
    234 schema:familyName Hendrickson
    235 schema:givenName Wayne A.
    236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240471215.59
    237 rdf:type schema:Person
    238 sg:person.013242604132.30 schema:affiliation grid-institutes:grid.418019.5
    239 schema:familyName Sweet
    240 schema:givenName Raymond W.
    241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013242604132.30
    242 rdf:type schema:Person
    243 sg:person.01365275476.29 schema:affiliation grid-institutes:grid.38142.3c
    244 schema:familyName Sodroski
    245 schema:givenName Joseph
    246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01365275476.29
    247 rdf:type schema:Person
    248 sg:person.0612551152.66 schema:affiliation grid-institutes:grid.21729.3f
    249 schema:familyName Kwong
    250 schema:givenName Peter D.
    251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0612551152.66
    252 rdf:type schema:Person
    253 sg:person.0756353131.25 schema:affiliation grid-institutes:grid.65499.37
    254 schema:familyName Wyatt
    255 schema:givenName Richard
    256 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0756353131.25
    257 rdf:type schema:Person
    258 sg:pub.10.1038/289366a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016242659
    259 https://doi.org/10.1038/289366a0
    260 rdf:type schema:CreativeWork
    261 sg:pub.10.1038/31514 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007469332
    262 https://doi.org/10.1038/31514
    263 rdf:type schema:CreativeWork
    264 sg:pub.10.1038/340571a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049274163
    265 https://doi.org/10.1038/340571a0
    266 rdf:type schema:CreativeWork
    267 sg:pub.10.1038/348411a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023911798
    268 https://doi.org/10.1038/348411a0
    269 rdf:type schema:CreativeWork
    270 sg:pub.10.1038/348419a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025743531
    271 https://doi.org/10.1038/348419a0
    272 rdf:type schema:CreativeWork
    273 sg:pub.10.1038/355740a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008705802
    274 https://doi.org/10.1038/355740a0
    275 rdf:type schema:CreativeWork
    276 sg:pub.10.1038/371037a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046282624
    277 https://doi.org/10.1038/371037a0
    278 rdf:type schema:CreativeWork
    279 sg:pub.10.1038/384179a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017723508
    280 https://doi.org/10.1038/384179a0
    281 rdf:type schema:CreativeWork
    282 sg:pub.10.1038/387426a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010263645
    283 https://doi.org/10.1038/387426a0
    284 rdf:type schema:CreativeWork
    285 sg:pub.10.1038/387527a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018440913
    286 https://doi.org/10.1038/387527a0
    287 rdf:type schema:CreativeWork
    288 sg:pub.10.1038/nsb1295-1075 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049045339
    289 https://doi.org/10.1038/nsb1295-1075
    290 rdf:type schema:CreativeWork
    291 grid-institutes:grid.21729.3f schema:alternateName Department of Biochemistry and Molecular Biophysics, Columbia University, 10032, New York, New York, USA
    292 Howard Hughes Medical Institute, Columbia University, 10032, New York, New York, USA
    293 schema:name Department of Biochemistry and Molecular Biophysics, Columbia University, 10032, New York, New York, USA
    294 Howard Hughes Medical Institute, Columbia University, 10032, New York, New York, USA
    295 rdf:type schema:Organization
    296 grid-institutes:grid.38142.3c schema:alternateName Department of Immunology and Infectious Diseases, Harvard School of Public Health, 02115, Boston, Massachusetts, USA
    297 schema:name Department of Cancer Immunology and AIDS, Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard School of Public Health, 02115, Boston, Massachusetts, USA
    298 Department of Immunology and Infectious Diseases, Harvard School of Public Health, 02115, Boston, Massachusetts, USA
    299 rdf:type schema:Organization
    300 grid-institutes:grid.412823.e schema:alternateName Department of Pediatrics, Tulane University Medical Center, 1430 Tulane Avenue, 70112, New Orleans, Louisiana, USA
    301 schema:name Department of Pediatrics, Tulane University Medical Center, 1430 Tulane Avenue, 70112, New Orleans, Louisiana, USA
    302 rdf:type schema:Organization
    303 grid-institutes:grid.418019.5 schema:alternateName Department of Immunology, SmithKline Beecham Pharmaceuticals, 709 Swedeland Road, 19406, King of Prussia, Pennsylvania, USA
    304 schema:name Department of Immunology, SmithKline Beecham Pharmaceuticals, 709 Swedeland Road, 19406, King of Prussia, Pennsylvania, USA
    305 rdf:type schema:Organization
    306 grid-institutes:grid.65499.37 schema:alternateName Department of Cancer Immunology and AIDS, Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard School of Public Health, 02115, Boston, Massachusetts, USA
    307 schema:name Department of Cancer Immunology and AIDS, Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard School of Public Health, 02115, Boston, Massachusetts, USA
    308 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...